Literature DB >> 2528079

Transluminal angioplasty of intracerebral vessels for cerebral arterial spasm: reversal of neurological deficits after delayed treatment.

S L Barnwell1, R T Higashida, V V Halbach, C F Dowd, C B Wilson, G B Hieshima.   

Abstract

We used intracerebral transluminal angioplasty to treat two episodes of symptomatic vasospasm in a patient recovering from an aneurysmal subarachnoid hemorrhage. The procedures were performed after medical therapies, intravascular volume expansion, and induced arterial hypertension failed to alleviate the patient's neurological condition. The first angioplasty, confined to the right middle cerebral and distal internal carotid arteries, took place more than 30 hours after the onset of left hemiplegia. Despite the subsequent discovery of a small parietal lobe infarct, it brought about a marked improvement in left motor function and may have also limited the spread of necrotic damage. The second angioplasty was necessitated when stenotic segments of the basilar and posterior cerebral arteries caused a 24-hour decline in the patient's mental status. Although delayed in relation to the onset of symptoms, it successfully reversed the patient's comatose state. The use of transluminal angioplasty for vasospasm is generally limited to cases where it can be performed shortly after the onset of neurological symptoms; delaying the procedure increases the risk of hemorrhage from reperfused areas of infarction. Our experience with this patient demonstrates that delayed angioplasty can improve vascular flow to ischemic territory, even after infarction, without complications and with resultant improvement in neurological function.

Entities:  

Mesh:

Year:  1989        PMID: 2528079     DOI: 10.1097/00006123-198909000-00017

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  7 in total

1.  Impact of percutaneous transluminal angioplasty for treatment of cerebral vasospasm on subarachnoid hemorrhage patient outcomes.

Authors:  Rakesh Khatri; Muhammad Zeeshan Memon; Haralabos Zacharatos; Ather M Taqui; Mushtaq H Qureshi; Gabriela Vazquez; M Fareed K Suri; Gustavo J Rodriguez; Ramachandra P Tummala; Mustapha A Ezzeddine; Adnan I Qureshi
Journal:  Neurocrit Care       Date:  2011-08       Impact factor: 3.210

2.  Predictors of outcome after endovascular treatment of cerebral vasospasm.

Authors:  Alejandro A Rabinstein; Jonathan A Friedman; Douglas A Nichols; Mark A Pichelmann; Robyn L McClelland; Edward M Manno; John L D Atkinson; Eelco F M Wijdicks
Journal:  AJNR Am J Neuroradiol       Date:  2004 Nov-Dec       Impact factor: 3.825

3.  Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm.

Authors:  Neeraj Badjatia; Mehmet A Topcuoglu; Johnny C Pryor; James D Rabinov; Christopher S Ogilvy; Bob S Carter; Guy A Rordorf
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

Review 4.  Interventional neuroradiology.

Authors:  S L Barnwell
Journal:  West J Med       Date:  1993-02

5.  Super-selective intra-arterial magnesium sulfate in combination with nicardipine for the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage.

Authors:  Qaisar A Shah; Muhammad Zeeshan Memon; M Fareed K Suri; Gustavo J Rodriguez; Osman S Kozak; Robert A Taylor; Ramachandra P Tummala; Gabriela Vazquez; Alexandros L Georgiadis; Adnan I Qureshi
Journal:  Neurocrit Care       Date:  2009-04-16       Impact factor: 3.210

6.  The Effect of a Single dose Dantrolene in Patients with Vasospasm Following Aneurysmal Subarachnoid Hemorrhage.

Authors:  Masih Sabouri; Mahmood Momeni; Fariborz Khorvash; Majid Rezvani; Homayon Tabesh
Journal:  Adv Biomed Res       Date:  2017-07-14

7.  In Premature Newborns Intraventricular Hemorrhage Causes Cerebral Vasospasm and Associated Neurodisability via Heme-Induced Inflammasome-Mediated Interleukin-1 Production and Nitric Oxide Depletion.

Authors:  Michael Eisenhut; Samyami Choudhury
Journal:  Front Neurol       Date:  2017-08-18       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.